Cyclopamine-competitive antagonists of SMO, like vismodegib and sonidegib, are approved for BCC patients with locally advanced or metastatic BCC unsuitable for surgery or radiation, helping control the disease and reducing tumor size [6]. Here, SMO is linked to skin basal cell carcinoma.